Table. 1.

Table. 1.

Demographics of liver cancer in Korea

Demographic HCC (C22.0) (n = 242,605) IHCC (C22.1) (n = 50,422) C22 others (liver cancer others) (n = 26,936) C22 (liver) (n = 319,963)
Age (yr)
00–39 8,051 (3.3) 712 (1.4) 1,130 (4.2) 9,893 (3.1)
40–49 37,579 (15.5) 2,970 (5.9) 2,715 (10.1) 43,264 (13.5)
50–59 72,610 (29.9) 8,761 (17.4) 5,844 (21.7) 87,215 (27.3)
60–69 66,291 (27.3) 14,819 (29.4) 7,233 (26.9) 88,343 (27.6)
70–79 43,221 (17.8) 15,636 (31.0) 6,673 (24.8) 65,530 (20.5)
≥ 80 14,853 (6.1) 7,524 (14.9) 3,341 (12.4) 25,718 (8.0)
Sex
Male 190,067 (78.3) 31,182 (61.8) 18,256 (67.8) 239,505 (74.9)
Female 52,538 (21.7) 19,240 (38.2) 8,680 (32.2) 80,458 (25.1)
First course of treatment
Any surgery 40,027 (16.5) 11,565 (22.9) 4,750 (17.6) 56,342 (17.6)
Non-surgical 99,474 (41.0) 10,607 (21.0) 5,174 (19.2) 115,255 (36.0)
No active treatment/ Unknown 103,104 (42.5) 28,250 (56.0) 17,012 (63.2) 148,366 (46.4)
Unknown
SEER Stage (2006–2019)
Localized 83,322 (49.8) 9,398 (23.4) 4,608 (31.7) 97,328 (43.8)
Regional 37,488 (22.4) 11,222 (28.0) 2,259 (15.6) 50,969 (23.0)
Distant 17,888 (10.7) 12,612 (31.5) 2,409 (16.6) 32,909 (14.8)
Unstaged 28,732 (17.2) 6,875 (17.1) 5,243 (36.1) 40,850 (18.4)

Values are presented as number (%).

HCC, hepatocellular carcinoma; IHCC, intrahepatic cholangiocarcinoma; SEER, Surveillance, Epidemiology, and End Results.

Ann Hepatobiliary Pancreat Surg 2022;26:211-9 https://doi.org/10.14701/ahbps.22-044
© 2022 Ann Hepatobiliary Pancreat Surg